trafficking protein particle complex subunit 6BGenealiases: NEDMEBA · TPC6
Q-omics provides the consensus-scored TRAPPC6B profile across patient tissues and cancer cell-line models. TRAPPC6B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TRAPPC6B is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, TRAPPC6B RNA expression shows 20,969 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where TRAPPC6B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAPPC6B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAPPC6B survival associations across molecular data types. TRAPPC6B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAPPC6B RNA expression–survival associations across cancer types. High TRAPPC6B expression shows unfavorable associations in ACC, LIHC, HNSC and STAD, but favorable associations in KIRC and BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TRAPPC6B RNA expression.
This table summarizes TRAPPC6B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TRAPPC6B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAPPC6B shows lower tumor expression in KIRC and THCA and higher tumor expression in HNSC, UCEC, CHOL and ESCA. The HNSC box plot shows higher TRAPPC6B RNA expression in tumor versus normal tissue (log2 FC = +0.954, t-test p < 0.001).
This table shows molecular features associated with TRAPPC6B in patient tissues and cancer cell lines. In patient samples, TRAPPC6B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TRAPPC6B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
